Management of Low-risk and Intermediate-risk Non-Muscle-invasive Bladder Carcinoma

Weijers Yme; Arentsen Harm C.; Arends Tom J. H.; Witjes J. Alfred

首页> 外文期刊>Hematology/Oncology Clinics of North America >Management of Low-risk and Intermediate-risk Non-Muscle-invasive Bladder Carcinoma

【24h】

Management of Low-risk and Intermediate-risk Non-Muscle-invasive Bladder Carcinoma

机译：低危和中危非肌肉浸润性膀胱癌的治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Non-muscle-invasive bladder cancer is a highly recurrent disease. The health care costs for non-muscle-invasive bladder cancer are a major burden for society. Bladder cancer treatment starts with a presumed complete transurethral resection of a bladder tumor. Despite international guidelines for perioperative and/or adjuvant intravesical instillation therapy in non-muscle-invasive bladder cancer, adequate worldwide application is lacking. In patients who do get adjuvant intravesical instillations, recurrences are still frequent. New therapies in non-muscle-invasive bladder cancer are unsatisfactory and still experimental.

机译：非肌肉浸润性膀胱癌是一种高度复发的疾病。非肌肉浸润性膀胱癌的医疗保健费用是社会的主要负担。膀胱癌的治疗始于假定的膀胱肿瘤完全经尿道切除术。尽管在非肌肉浸润性膀胱癌中围手术期和/或辅助膀胱内滴注疗法有国际指南，但仍缺乏足够的全球应用。在确实接受辅助膀胱内滴注的患者中，复发仍很频繁。非肌肉浸润性膀胱癌的新疗法仍不能令人满意，仍处于试验阶段。

著录项

来源
《Hematology/Oncology Clinics of North America》 |2015年第2期|共7页
作者
Weijers Yme; Arentsen Harm C.; Arends Tom J. H.; Witjes J. Alfred;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Non-muscle-invasive bladder cancer; Risk groups; Intermediate risks; Low risk; Treatment;

机译：非肌肉浸润性膀胱癌;风险组;中度风险;低风险;治疗;

相似文献

外文文献
中文文献
专利

1. Management of Low-risk and Intermediate-risk Non-Muscle-invasive Bladder Carcinoma [J] . Weijers Yme, Arentsen Harm C., Arends Tom J. H., Hematology/Oncology Clinics of North America . 2015,第2期

机译：低危和中危非肌肉浸润性膀胱癌的治疗
2. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer [J] . Montorsi Francesco, Moschini Marco, Necchi Andrea BJU international . 2020,第6期

机译：口径：用丝裂霉素-C的化学膨胀性的II期随机可行性试验，低危非肌肉侵入性膀胱癌的手术管理
3. A Cost-effectiveness Analysis of Management of Low-risk Non-muscle-invasive Bladder Cancer Using Office-based Fulguration [J] . Al Awamlh Bashir Al Hussein, Lee Richard, Chughtai Bilal, Urology . 2015,第2期

机译：使用基于办公室的引流术管理低风险非肌肉浸润性膀胱癌的成本效益分析
4. Differentiating Bladder Carcinoma from Bladder Wall Using 3D Textural Features: An Initial Study [C] . Xiaopan Xu, Xi Zhang, Yang Liu, Conference on medical imaging . 2016

机译：使用3D纹理特征区分膀胱癌和膀胱壁的初步研究
5. Role of the Nuclear Receptor PPARγ in Clear Cell Renal and Bladder Urotheial Carcinoma [D] . Sanchez, Danielle J. 2019

机译：核受体PPARγ在透明细胞肾和膀胱尿路上皮癌中的作用
6. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy [O] . Zhenxing Yang, Bingqiang Fu, Luqiang Zhou, 2019

机译：RRM1预测接受吉西他滨单一治疗的高中度非肌肉浸润性膀胱癌患者的临床结局
7. Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation [O] . 2016

机译：中风险非肌肉浸润性膀胱癌患者膀胱内化疗后复发概率的预测模型，包括外部验证

Management of Low-risk and Intermediate-risk Non-Muscle-invasive Bladder Carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅